PUBLIC COMPANY
save$NTLAIntellia Therapeutics, Inc.
$NTLA12.44-6.33%Cambridge, MA, USupdated 8h ago
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- —Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
- phase3HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
- phase3A Phase 3 Study of NTLA-2001 in ATTRv-PN
- phase3MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- phase2NTLA-2002 in Adults With Hereditary Angioedema (HAE)
- phase1Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)
- —Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002
- phase2NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (6)
- Mar 1, 26grantLEONARD JOHN M · President and CEO156,400 sh
- Mar 1, 26grantLEONARD JOHN M · President and CEO225,400 sh
- Mar 1, 26grantBASTA JAMES · EVP, General Counsel46,080 sh
- Mar 1, 26grantBASTA JAMES · EVP, General Counsel65,829 sh
- Mar 1, 26grantLebwohl David · EVP, Chief Medical Officer9,943 sh
- Mar 1, 26grantLebwohl David · EVP, Chief Medical Officer14,204 sh
🐶 Hiring Signal
next earnings Nov 5, 2026
News
- ‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culpritEarly indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.biopharma_dive · 13d ago
- Fulcrum exploring a potential sale after FDA sidelined its sickle cell drugFulcrum’s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis and Intellia Therapeutics.biopharma_dive · 2mo ago
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that